{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:25:24Z","timestamp":1790915124580,"version":"4.1.0"},"reference-count":41,"publisher":"The Journal of Rheumatology","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2010,4]]},"abstract":"<jats:sec><jats:title>Objective.<\/jats:title><jats:p><jats:italic>Pneumocystis<\/jats:italic>pneumonia (PCP) occurs in immunocompromised hosts, in both the presence and absence of human immunodeficiency virus (HIV) infection, with substantial morbidity and a heightened mortality. We assessed practice patterns among rheumatologists for prescribing PCP prophylaxis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods.<\/jats:title><jats:p>Invitations to an online international survey were e-mailed to 3150 consecutive members of the American College of Rheumatology.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results.<\/jats:title><jats:p>Completed surveys were returned by 727 (23.1%) members. Among respondents, 505 (69.5%) reported prescribing prophylaxis. Factors associated with significantly higher frequency of prescribing PCP prophylaxis included female gender (OR 1.47, p = 0.03), US-based (OR 1.77, p = 0.004), academic-based (OR 2.75, p &lt; 0.001), in practice less than 10 years (OR 4.08, p &lt; 0.001), having previously treated PCP (OR 2.62, p &lt; 0.001), and in a practice with a higher proportion of patients maintained on chronic glucocorticoids (OR 2.04, p &lt; 0.001) or other immunosuppressant medications (OR 3.19, p = 0.003). In multivariate analysis, rheumatologists early in their careers and those with academic and US-based practices were more likely to prescribe prophylaxis. Among prescribers, the most important determinants for issuing prophylaxis were treatment regimen (68.6%), rheumatologic diagnosis (9.3%), and medication dosage (8.3%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion.<\/jats:title><jats:p>Nearly one-third (30%) of the rheumatologists surveyed reported that they never prescribed PCP prophylaxis. While the patient characteristics for which prophylaxis was prescribed varied widely, physician demographics were strongly predictive of PCP prophylaxis use. These findings suggest that development of consensus guidelines might influence clinical decision-making regarding PCP prophylaxis in HIV-negative patients with rheumatologic diagnoses.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.090843","type":"journal-article","created":{"date-parts":[[2010,3,2]],"date-time":"2010-03-02T03:55:01Z","timestamp":1267502101000},"page":"792-799","source":"Crossref","is-referenced-by-count":46,"title":["A Survey of Rheumatologists\u2019 Practice for Prescribing Pneumocystis Prophylaxis"],"prefix":"10.3899","volume":"37","author":[{"given":"DEANNA","family":"CETTOMAI","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ALLAN C.","family":"GELBER","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LISA","family":"CHRISTOPHER-STINE","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2010,3,1]]},"reference":[{"key":"2018112909224127000_37.4.792.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra032588"},{"key":"2018112909224127000_37.4.792.2","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1097\/00063198-199605000-00014","article-title":"Respiratory infections in HIV-negative immunocompromised patients","volume":"2","author":"Santamauro","year":"1996","journal-title":"Curr Opin Pulm Med"},{"key":"2018112909224127000_37.4.792.3","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.17.4.770-782.2004"},{"key":"2018112909224127000_37.4.792.4","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1995.00430220094010"},{"key":"2018112909224127000_37.4.792.5","doi-asserted-by":"publisher","DOI":"10.1080\/00365540601150497"},{"key":"2018112909224127000_37.4.792.6","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-006-9250-x"},{"key":"2018112909224127000_37.4.792.7","first-page":"612","article-title":"Pneumocystis carinii pneumonia in patients without HIV infection","volume":"86","author":"Saksasithon","year":"2003","journal-title":"J Med Assoc Thai"},{"key":"2018112909224127000_37.4.792.8","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.1999.03052.x"},{"key":"2018112909224127000_37.4.792.9","first-page":"170","article-title":"Pneumocystis carinii pneumonia following corticosteroid therapy for giant cell arteritis","volume":"90","author":"Crayton","year":"1991","journal-title":"Wis Med J"},{"key":"2018112909224127000_37.4.792.10","doi-asserted-by":"publisher","DOI":"10.1097\/01.rhu.0000221794.24431.36"},{"key":"2018112909224127000_37.4.792.11","first-page":"246","article-title":"Pneumocystis carinii pneumonia in the course of connective tissue disease: report of 34 cases","volume":"21","author":"Godeau","year":"1994","journal-title":"J Rheumatol"},{"key":"2018112909224127000_37.4.792.12","doi-asserted-by":"publisher","DOI":"10.1007\/s10165-006-0502-6"},{"key":"2018112909224127000_37.4.792.13","first-page":"1186","article-title":"Risk factors for Pneumocystis carinii pneumonia in patients with polymyositis\/dermatomyositis or systemic lupus erythematosus","volume":"23","author":"Kadoya","year":"1996","journal-title":"J Rheumatol"},{"key":"2018112909224127000_37.4.792.14","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3109\/PL00021707","article-title":"Prediction of and prophylaxis against Pneumocystis pneumonia in patients with connective tissue diseases undergoing medium- or high-dose corticosteroid therapy","volume":"16","author":"Ogawa","year":"2005","journal-title":"Mod Rheumatol"},{"key":"2018112909224127000_37.4.792.15","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/j.1445-5994.2007.01382.x","article-title":"Audit of pneumocystis pneumonia in patients seen by the Christchurch Hospital rheumatology service over a 5-year period","volume":"37","author":"Meuli","year":"2007","journal-title":"Intern Med J"},{"key":"2018112909224127000_37.4.792.16","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199904)42:4<780::AID-ANR23>3.0.CO;2-M"},{"key":"2018112909224127000_37.4.792.17","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1997.00440340145015"},{"key":"2018112909224127000_37.4.792.18","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1995.00430080122016"},{"key":"2018112909224127000_37.4.792.19","doi-asserted-by":"publisher","DOI":"10.1007\/s10165-005-0443-5"},{"key":"2018112909224127000_37.4.792.20","doi-asserted-by":"publisher","DOI":"10.1177\/096120339200100607"},{"key":"2018112909224127000_37.4.792.21","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200008)43:8<1841::AID-ANR21>3.0.CO;2-Q"},{"key":"2018112909224127000_37.4.792.22","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-137-5_Part_2-200209031-00002"},{"key":"2018112909224127000_37.4.792.23","doi-asserted-by":"crossref","unstructured":"Green H Paul M Vidal L Leibovici L . Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients. Cochrane Database Syst Rev 2007:CD005590.","DOI":"10.1002\/14651858.CD005590.pub2"},{"key":"2018112909224127000_37.4.792.24","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0b013e31817a7e30"},{"key":"2018112909224127000_37.4.792.25","first-page":"555","article-title":"[Pneumocystis carinii pneumonia. Complications of cytotoxic treatment in a systemic vasculitis]","volume":"12","author":"Gamboa","year":"1995","journal-title":"An Med Interna"},{"key":"2018112909224127000_37.4.792.26","doi-asserted-by":"publisher","DOI":"10.1136\/ard.54.12.991"},{"key":"2018112909224127000_37.4.792.27","first-page":"615","article-title":"Increased risk of Pneumocystis carinii pneumonia in patients with Wegener\u2019s granulomatosis","volume":"11","author":"Jarrousse","year":"1993","journal-title":"Clin Exp Rheumatol"},{"key":"2018112909224127000_37.4.792.28","doi-asserted-by":"publisher","DOI":"10.1378\/chest.99.1.143"},{"key":"2018112909224127000_37.4.792.29","first-page":"795","article-title":"Pneumocystis carinii pneumonia: a major complication of immunosuppressive therapy in patients with Wegener\u2019s granulomatosis","volume":"151","author":"Ognibene","year":"1995","journal-title":"Am J Respir Crit Care Med"},{"key":"2018112909224127000_37.4.792.30","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1164\/ajrccm.152.6.8520798","article-title":"Pneumocystis carinii pneumonia: a major complication of immunosuppressive therapy in patients with Wegener\u2019s granulomatosis","volume":"152","author":"Vincent","year":"1995","journal-title":"Am J Respir Crit Care Med"},{"key":"2018112909224127000_37.4.792.31","doi-asserted-by":"publisher","DOI":"10.4065\/71.1.5"},{"key":"2018112909224127000_37.4.792.32","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-4-42"},{"key":"2018112909224127000_37.4.792.33","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1995.00430110015002"},{"key":"2018112909224127000_37.4.792.34","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1093\/milmed\/161.1.58","article-title":"Low-dose methotrexate as a risk factor for Pneumocystis carinii pneumonia","volume":"161","author":"Krebs","year":"1996","journal-title":"Mil Med"},{"key":"2018112909224127000_37.4.792.35","doi-asserted-by":"publisher","DOI":"10.3109\/03009749409102137"},{"key":"2018112909224127000_37.4.792.36","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-200303000-00002"},{"key":"2018112909224127000_37.4.792.37","doi-asserted-by":"publisher","DOI":"10.1007\/s10165-005-0395-9"},{"key":"2018112909224127000_37.4.792.38","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/j.1532-5415.1997.tb00949.x","article-title":"Opportunistic infections in patients with temporal arteritis treated with corticosteroids","volume":"45","author":"Hedderwick","year":"1997","journal-title":"J Am Geriatr Soc"},{"key":"2018112909224127000_37.4.792.39","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.11150\/kansenshogakuzasshi1970.73.1123","article-title":"Efficacy of sulfamethoxazole-trimethoprim administration in the prevention of Pneumocystis carinii pneumonia in patients with connective tissue disease","volume":"73","author":"Okada","year":"1999","journal-title":"Kansenshogaku Zasshi"},{"key":"2018112909224127000_37.4.792.40","first-page":"973","article-title":"Screening for proteinuria in patients with lupus: a survey of practice preferences among American rheumatologists","volume":"34","author":"Siedner","year":"2007","journal-title":"J Rheumatol"},{"key":"2018112909224127000_37.4.792.41","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.071530"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.090843","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,24]],"date-time":"2024-03-24T14:38:57Z","timestamp":1711291137000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.090843"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3,1]]},"references-count":41,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2010,4,1]]},"published-print":{"date-parts":[[2010,4]]}},"alternative-id":["10.3899\/jrheum.090843"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.090843","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,3,1]]}}}